| Mutya Harsch |
Mutya Harsch is currently the Director at VYNE Pharmaceuticals Ltd. and also holds the position of Secretary, Chief Legal Officer & General Counsel at VYNE Therapeutics, Inc. Previously, Ms. Harsch served as an Independent Director at Satsuma Pharmaceuticals, Inc. and as Secretary, Chief Legal Officer & General Counsel at Menlo Therapeutics, Inc. Ms. Harsch also worked as an Assistant General Counsel at Warner Chilcott, Inc. from 2003 to 2005 and as Special Counsel-Mergers & Acquisitions at Cooley LLP from 2015 to 2017. Additionally, Ms. Harsch held the role of Chief Legal Officer & General Counsel at VYNE Pharmaceuticals, Inc. from 2018 to 2020. Ms. Harsch completed undergraduate and graduate degrees at the University of California, Berkeley. |
| Ilan Hadar |
Ilan Hadar is currently the Director at Silexion Therapeutics Ltd. and the Chief Executive & Financial Officer at PainReform Ltd. Previously, he held positions as the Finance Director at BAE Systems Rokar International Ltd., Pfizer Pharmaceuticals Israel Ltd., and VYNE Pharmaceuticals Ltd. He also served as the Independent Director at Kadimastem Ltd. and the Chief Financial Officer at Mango DSP Ltd. Additionally, he worked as the Chief Financial Officer & Treasurer at Menlo Therapeutics, Inc. and the Vice President-Finance & Business Development at Millennium Food-Tech - LP. Mr. Hadar's education includes an undergraduate degree and an MBA from The Hebrew University of Jerusalem. |
| Mitchell Shirvan |
Mitchell Shirvan is currently the Chief Executive Officer at D.H.S Medical Ltd. He also holds the position of Vice President-Innovation & Discovery at VYNE Pharmaceuticals Ltd. since 2017. Previously, he served as the Chief Executive Officer at Macrocure Ltd. and as the Senior Director-Global Strategic Business at Teva Pharmaceutical Industries Ltd. Dr. Shirvan holds an MBA from the University of Bradford and a doctorate from The Hebrew University of Jerusalem. |
